Navigation Links
Cepheid Reports Record Revenue of $44.8 Million
Date:5/1/2008

are also starting to see accounts purchase additional modules to accommodate potentially increasing test demand."

Cepheid's product development programs continue to be on track. As expected, the Company filed a 510(k) with the FDA for the Xpert MRSA/SA -- SSTI (Skin and Soft Tissue Infection) product in March and expects to submit a 510(k) for the Xpert MRSA/SA -- BC (Blood Culture) product during the current quarter. The development of the GeneXpert Infinity-48 is on track with shipment expected to begin in December of this year. A functional prototype of the GeneXpert Infinity-48 is expected to be unveiled at the American Association of Clinical Chemistry (AACC) meeting in July.

Business Outlook

For fiscal year 2008, the Company is raising its previously provided revenue guidance:

-- Total revenue is expected to be in the range of $183 million to

$190 million.

o Product sales are expected to be in the range of $176 million to

$181 million.

o Xpert MRSA test sales are expected to be in the range of

$52 million to $55 million.

-- GAAP net loss for 2008 is expected to be in the range of $10 million to

$12 million, or $(.18) to $(.21) per share.

-- Non-GAAP net income is expected to be in the range of $3 million to

$5 million, or $.05 to $.08 income per fully-diluted share. Non-GAAP

net income excludes approximately $14 million related to stock

compensation expense and $1 million related to the amortization of

acquired intangibles.

Safe Harbor Statement

This press release contains forward-looking statements that are not purely historical regarding Cepheid's or its management's intentions, beliefs, expectations and strategies for the future, including those relating to potential growth in clinical products sales, future product releases, future regulatory clearance of products, other future development a
'/>"/>

SOURCE Cepheid
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Cepheid Selected as Vendor of Choice by Connecticut Hospital Association Shared Services Program for Molecular MRSA Surveillance Testing
2. Cepheid Comments on Study Regarding MRSA Surveillance Reported in the Journal of the American Medical Association
3. Cepheid to Present at the Needham Tenth Annual Growth Stock Conference
4. Cepheid and Broadlane Sign Group Purchasing Contract for GeneXpert(R) Systems and Xpert(TM) Molecular Diagnostic Tests, Including Xpert MRSA
5. Cepheid Schedules Teleconference and Webcast for Third Quarter 2007 Results
6. Cepheid to Present at ThinkEquity Partners 5th Annual Growth Conference
7. Cephalon Reports Strong First Quarter Earnings
8. Haemonetics Reports Strong Results for Fourth Quarter and Fiscal Year End 2008 and Issues Guidance for Continued Strong Growth in Fiscal 2009
9. Nu Skin Enterprises Reports First-Quarter 2008 Results
10. Cardinal Health Reports Third Quarter Results
11. BioMed Realty Trust Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 2014 (HealthDay News) -- The U.S. National Institutes ... funding in scientific trials to encourage researchers to ... The supplemental monies were provided to 82 ... immunology, cardiovascular physiology, neural circuitry, and behavioral health, ... "This funding strategy demonstrates our commitment to moving ...
(Date:9/23/2014)... Center have published the first study to extensively ... The Journal of Allergy and Clinical Immunology ... that has high levels of eosinophils in the ... allergy-associated-immune mechanisms and has a gene expression pattern ... related disorder, eosinophilic esophagitis (EoE). , Eosinophilic ...
(Date:9/23/2014)... 23, 2014) Laparoscopic cholecystectomy, a minimally invasive procedure to ... abdominal surgeries in the U.S. Yet medical centers around ... with some moving patients quickly into surgery while others ... the American Journal of Surgery , researchers found ... rather than rushing the patients into the operating room ...
(Date:9/23/2014)... Act "Obamacare" was signed into law in ... healthcare system since the 1960s. Designed to provide medical ... as an unwarranted intrusion into the affairs of private ... of healthcare systems in six Western countries, published last ... a move away from privatized medicine toward state-sponsored healthcare ...
(Date:9/23/2014)... 2014 Royal Sport Ultra Clean 100 ... LTD family of premium sports nutrition products. Its gluten ... Whey protein without artificial colors or dyes, fillers, added ... available on shelves at select GNC retailers, on GNC.com, ... is offering a limited time special on its products. ...
Breaking Medicine News(10 mins):Health News:NIH Adds $10M to Encourage Gender Balance in Clinical Trials 2Health News:Advancing the understanding of an understudied food allergy disorder 2Health News:Advancing the understanding of an understudied food allergy disorder 3Health News:Study finds gallbladder surgery can wait 2Health News:Life, liberty, and the pursuit of healthcare? 2Health News:Sports Nutrition Brand, Royal Sport LTD, Introduces 'Clean,' Gluten Free Protein Supplement, Royal Sport Ultra Clean 100™ 2
... intensive therapy works well, study finds , THURSDAY, Aug. ... (RA) who respond poorly to standard treatment with methotrexate ... (TNF) blockers, a Swedish study suggests. , Previous research ... patients have a good response to methotrexate therapy and ...
... , , MISSION VIEJO, Calif., ... the parent company of the Ensign(TM) group of skilled nursing, rehabilitative care ... quarter of fiscal year 2009. , , (Logo: ... Include: , , Total revenue was ...
... , , RANCHO CORDOVA, Calif., ... ), a leading supplier of innovative products for processing and storing ... BMC ("Res-Q") System, an automated cell processing medical device for the ... , , The Res-Q System processes bone ...
... American Health Assistance Foundation Researcher Is Featured Facilitator , ... Health Assistance Foundation and Asbury Methodist Village are partnering to host a ... Project to bring awareness to the community about this devastating disease, ... Part one of the Momentum in Science ...
... ... The Angelman Syndrome Foundation, www.angelman.org , announced the ... direct the organization,s rapidly increasing research funding. The ATRI will also ... scientists worldwide to share discoveries and treatments for this neuro-genetic disorder. ...
... BETHESDA, Md., Aug. 6 /PRNewswire-Asia/ -- , ... CHDX ), a leading,independent American provider ... Republic of China, today announced that the Company,s,Western-style ... a comprehensive, international-standard oncology program, called "New,Hope," at ...
Cached Medicine News:Health News:TNF Blockers May Help Some With Rheumatoid Arthritis 2Health News:The Ensign Group Reports Second Quarter 2009 Earnings of $0.39 per Share; Reaffirms 2009 EPS Guidance 2Health News:The Ensign Group Reports Second Quarter 2009 Earnings of $0.39 per Share; Reaffirms 2009 EPS Guidance 3Health News:The Ensign Group Reports Second Quarter 2009 Earnings of $0.39 per Share; Reaffirms 2009 EPS Guidance 4Health News:The Ensign Group Reports Second Quarter 2009 Earnings of $0.39 per Share; Reaffirms 2009 EPS Guidance 5Health News:The Ensign Group Reports Second Quarter 2009 Earnings of $0.39 per Share; Reaffirms 2009 EPS Guidance 6Health News:The Ensign Group Reports Second Quarter 2009 Earnings of $0.39 per Share; Reaffirms 2009 EPS Guidance 7Health News:The Ensign Group Reports Second Quarter 2009 Earnings of $0.39 per Share; Reaffirms 2009 EPS Guidance 8Health News:The Ensign Group Reports Second Quarter 2009 Earnings of $0.39 per Share; Reaffirms 2009 EPS Guidance 9Health News:The Ensign Group Reports Second Quarter 2009 Earnings of $0.39 per Share; Reaffirms 2009 EPS Guidance 10Health News:The Ensign Group Reports Second Quarter 2009 Earnings of $0.39 per Share; Reaffirms 2009 EPS Guidance 11Health News:The Ensign Group Reports Second Quarter 2009 Earnings of $0.39 per Share; Reaffirms 2009 EPS Guidance 12Health News:The Ensign Group Reports Second Quarter 2009 Earnings of $0.39 per Share; Reaffirms 2009 EPS Guidance 13Health News:ThermoGenesis Announces Launch of Res-Q System; New Device Expands Company's Presence in Bone Marrow Sector 2Health News:ThermoGenesis Announces Launch of Res-Q System; New Device Expands Company's Presence in Bone Marrow Sector 3Health News:American Health Assistance Foundation & Asbury Methodist Village to Host Special Community Screening and Discussion of the HBO Series, The Alzheimer's Project 2Health News:American Health Assistance Foundation & Asbury Methodist Village to Host Special Community Screening and Discussion of the HBO Series, The Alzheimer's Project 3Health News:Angelman Syndrome Foundation Takes Major Step Toward Furthering Research Efforts 2Health News:Angelman Syndrome Foundation Takes Major Step Toward Furthering Research Efforts 3Health News:Chindex International, Inc. Launches World-Class Cancer Treatment Center 2Health News:Chindex International, Inc. Launches World-Class Cancer Treatment Center 3Health News:Chindex International, Inc. Launches World-Class Cancer Treatment Center 4
(Date:9/23/2014)... , Sept. 23, 2014 Research and ... "Biopharmaceutical and Vaccine Production Markets" report to their ... new therapies and vaccines - including products to treat ... still huge challenges during the final stages of clinical ... and how to risk production capital to upscale while ...
(Date:9/23/2014)... 23, 2014  SiteOne Therapeutics Inc. today announced the ... by Sears Capital Management and Biobrit LLC, with additional ... the $1.5 million financing positions SiteOne to advance its ... to further develop its technology platform for long-acting local ... In conjunction with the financing, Lowell Sears ...
(Date:9/23/2014)...   COTA, Inc. today announced it has ... A funding round led by Horizon Healthcare Services, Inc. ... big data platform designed by practicing oncologists to deliver ... care in support of healthcare,s new value-based reimbursement model. ... of the COTA platform, hire biostatisticians, outcome analysts, data ...
Breaking Medicine Technology:Biopharmaceutical and Vaccine Production Markets 2Biopharmaceutical and Vaccine Production Markets 3SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 2SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 3COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 2COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 3COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 4
... -- Weikang Bio-technology Group, Inc. (the "Company," "Weikang" or ... all of its management departments into the building it ... Chengde Street in the Daowai District of Harbin, the ... of the building. Mr. Yin Wang, the ...
... Dec. 27, 2011  PharmacoFore, Inc., a privately held biopharmaceutical ... equity financing from Founders Fund and the addition ... Board of Directors.   PharmacoFore uses innovative ... treating a variety of conditions related to the ...
Cached Medicine Technology:Weikang Bio-technology Group, Inc. Completes HQ Relocation After Purchasing Building for $14 Million and Answers Questions About its Third Quarter Financials 2Weikang Bio-technology Group, Inc. Completes HQ Relocation After Purchasing Building for $14 Million and Answers Questions About its Third Quarter Financials 3PharmacoFore, Inc. Secures $10 Million in Equity Financing From Founders Fund 2
A system with integrated pupil camera and 7" examination monitor. An easy to use configuration....
... Laserex Tango ophthalmic laser system provides two ... laser and a photodisruptor for posterior capsulotomy ... frequency-doubled Nd:YAG producing pulsed 532 nm light. ... 1064 nm. The appropriate laser can be ...
Extremely thin and smooth jaws, jaws open to 5.5 mm, cross action....
Flat handle cross action....
Medicine Products: